vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 33.1% in January

by · The Markets Daily

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily volume of 29,400 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 target price on the stock.

View Our Latest Stock Analysis on vTv Therapeutics

vTv Therapeutics Price Performance

VTVT traded up $0.96 during mid-day trading on Friday, hitting $15.62. The stock had a trading volume of 13,070 shares, compared to its average volume of 7,390. The stock’s fifty day simple moving average is $14.76 and its 200-day simple moving average is $15.13. The firm has a market capitalization of $49.83 million, a price-to-earnings ratio of -3.45 and a beta of 0.69. vTv Therapeutics has a 1-year low of $8.03 and a 1-year high of $30.99.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC bought a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.

Read More